Table 1 Patients’ clinical characteristics, PET indices, and serum inflammatory biomarker levels
Untreated (n = 24) | Treated (n = 12) | |||
|---|---|---|---|---|
axSpA (n = 7) | pSpA (n = 17) | axSpA (n = 3) | pSpA (n = 9) | |
Age (year) | 49 ± 22 | 49 ± 12 | 67 ± 17 | 58 ± 15 |
Period from onset of SpA (month) | 45 ± 33 | 31 ± 38 | 56 ± 39 | 64 ± 65 |
Treatment period (month) | – | – | 41 ± 34 | 53 ± 60 |
Sex | ||||
Male | 2 | 11 | 1 | 6 |
Female | 5 | 6 | 2 | 3 |
HLA-B27 positive rate | 14.3% (n = 7) | 16.7% (n = 12) | 0% (n = 1) | 0% (n = 3) |
PET indices | ||||
MaxSUVmax | 5.24 ± 5.81 | 5.63 ± 4.52 | 3.87 ± 1.42 | 5.21 ± 3.37 |
Number of positive regions | 7 ± 5 | 11 ± 6 | 8 ± 6 | 12 ± 6 |
Total score | 8 ± 6 | 14 ± 11 | 10 ± 8 | 15 ± 9 |
Serum biomarkers | ||||
CRP (mg/dL) | 0.70 ± 1.11 (n = 7) | 1.99 ± 2.39 (n = 17) | 0.76 ± 0.61 (n = 3) | 0.65 ± 0.52 (n = 9) |
ESR (mm/1 h) | 27 ± 17 (n = 5) | 34 ± 22 (n = 10) | 37 ± 31 (n = 3) | 25 ± 24 (n = 3) |
MMP-3 (ng/mL) | 70.6 ± 34.0 (n = 5) | 120.6 ± 68.2 (n = 13) | 94.3 ± 37.1 (n = 2) | 90.7 ± 68.4 (n = 6) |